logo-loader

Nextleaf Solutions completes acquisition of its Nextleaf Labs cannabis processing subsidiary

Published: 09:35 30 Jul 2020 EDT

NEXTLEAF SOLUTIONS Ltd. -
Nextleaf owns a portfolio of 40 issued patents and over 60 pending patents for the extraction, purification, and formulation of cannabinoids

Nextleaf Solutions Ltd. (CSE:OILS) (OTCQB:OILFF), announced Thursday that it has completed the previously announced acquisition of all of the issued and outstanding shares of Nextleaf Labs Ltd., its subsidiary which holds a Health Canada standard processing and research licenses under the Cannabis Act.

The closing of the acquisition represents an important milestone for the company, allowing it to continue the commercialization of its intellectual property (IP) portfolio through the production and wholesale of THC and CBD based oils and concentrates by Nextleaf Labs.

READ: Nextleaf wins patent for THC-enhancing prodrug THC-O-Acetate

The company owns a portfolio of 40 issued patents and over 60 pending patents for the extraction, purification, and formulation of cannabinoids.

As consideration for the acquisition, Nextleaf issued 1,000,000 common shares to the sole shareholder of Nextleaf Labs at a deemed price of $0.385 per share for aggregate consideration of $385,000. 250,000 Shares were released to the seller on closing, with the remaining 750,000 shares subject to an escrow agreement providing for the release of such Shares in three equal tranches every six months. All shares issued are subject to a four month and one day hold period in accordance with Canadian securities laws.

Nextleaf is Canada's most innovative cannabis extractor, developing technology for extracting and distilling cannabinoids. It provides extraction services and wholesale of THC and CBD oils through Nextleaf Labs, a Health Canada licensed standard processor.

The group’s proprietary closed-loop extraction plant in Metro Vancouver has a design capacity to process 600 kg per day of dried cannabis biomass into distilled oils.

Nextleaf is the first public company to be issued US patents for industrial-scale extraction and distillation of cannabinoids.

Contact the author at jon.hopkins@proactiveinvestors.com

Xeris Biopharma Surpasses 2023 Expectations with Strategic Moves Poised for...

Xeris Biopharma CEO Paul Edick joined Steve Darling from Proactive to share news the company had a successful 2023, with a final tally of 164 million USD, which is at the upper end of their forecast. The company concluded the year with 72 million USD in cash, surpassing their initial projections...

12 hours, 45 minutes ago